Influenza vaccination in liver transplant recipients

Transplantation. 1999 Mar 15;67(5):753-5. doi: 10.1097/00007890-199903150-00019.


Background: The immunogenicity of the trivalent inactivated influenza split virus vaccine (Infusplit SSW 97/98) containing A/Bayern/07/95 (H1N1)-like (A/Johannesburg/82/96 [NIB-39]), A/Wuhan/359/95 (H3N2)-like (A/Nanchang/933/95 [Resvir-0]), and B/Beijing/184/93-like (B/Harbin/7/94) hemagglutinin antigens was tested in liver transplant recipients (TXL-R).

Subjects and methods: Serum antibody titers were determined 21+/-2 days after a single vaccination in 62 adult TXL-R and 59 adult volunteers.

Results: Protective postimmunization antibody titers for the three antigens were similar in TXL-R (protection rates 92%, 92%, and 95%) and the comparison group (97%, 100%, and 100%). Adverse reactions were mild and less frequent in TXL-R. A significant decrease of CD8+CD38+ lymphocytes after vaccination was found in TXL-R. No association between antibody response and age, gender, time interval since transplantation, anti-hepatitis B surface antigen immunoprophylaxis, or immunosuppressive medication was detected.

Conclusion: Our results show that the vaccine is safe and effective and should be recommended to TXL-R.

Publication types

  • Clinical Trial

MeSH terms

  • ADP-ribosyl Cyclase
  • ADP-ribosyl Cyclase 1
  • Adult
  • Antibodies, Viral / biosynthesis
  • Antigens, CD*
  • Antigens, Differentiation / analysis
  • Antigens, Viral / immunology
  • CD8 Antigens / analysis
  • Humans
  • Influenza Vaccines / immunology*
  • Liver Transplantation / immunology*
  • Lymphocytes / immunology
  • Membrane Glycoproteins
  • NAD+ Nucleosidase / analysis
  • Vaccination


  • Antibodies, Viral
  • Antigens, CD
  • Antigens, Differentiation
  • Antigens, Viral
  • CD8 Antigens
  • Influenza Vaccines
  • Membrane Glycoproteins
  • ADP-ribosyl Cyclase
  • CD38 protein, human
  • NAD+ Nucleosidase
  • ADP-ribosyl Cyclase 1